What causes menstrual cramps
Primary dysmenorrhea (menstrual cramps without identifiable structural cause) affects 50–90% of women of reproductive age. The mechanism is well established:
- During menstruation, endometrial cells release arachidonic acid (AA) from cell membranes
- COX-2 converts AA to prostaglandin PGH2
- PGH2 is converted to PGF2α (prostaglandin F2 alpha) and PGE2 — both of which cause uterine muscle contraction (PGF2α primarily), sensitise pain receptors, and trigger systemic symptoms (nausea, headache, diarrhoea associated with severe dysmenorrhea)
Women with severe dysmenorrhea have significantly higher PGF2α concentrations in menstrual fluid than those with mild pain. NSAIDs (ibuprofen, naproxen) work by inhibiting COX-2 and reducing prostaglandin production — this is why they are more effective for dysmenorrhea than pure analgesics like paracetamol.
The GLA-PGE1 pathway: why it’s relevant to menstrual pain
The prostaglandin system operates through two competing pathways:
- Pro-inflammatory pathway: Arachidonic acid (omega-6, from meat, eggs, dairy) → PGE2, PGF2α, TXA2 — causes cramps, pain, and inflammation
- Anti-inflammatory pathway: GLA → DGLA (dihomo-gamma-linolenic acid) → PGE1, 15-OH-DGLA — inhibits uterine contractions, competes with PGF2α production, and reduces inflammatory eicosanoids
DGLA, the metabolic product of GLA, directly inhibits 5-lipoxygenase (5-LOX) and has documented anti-spasmodic effects on smooth muscle — including uterine smooth muscle. PGE1 (from DGLA via COX-1) is vasodilatory and anti-aggregatory, opposing the vasoconstrictive and contractile effects of PGF2α.
This is the same mechanism behind evening primrose oil (EPO) supplementation for dysmenorrhea — EPO is rich in GLA (8–14%), and several trials have tested EPO for menstrual symptoms with modest positive results.
Spirulina’s GLA content and comparison to EPO
Spirulina contains approximately 0.6–1% GLA by weight — providing 30–60 mg GLA per 5 g serving.
Evening primrose oil provides 500–1,500 mg GLA per capsule at standard doses (2–4 g/day). This means spirulina at 5 g/day provides roughly 3–10% of the GLA dose used in EPO dysmenorrhea trials.
Conclusion: spirulina’s GLA alone is insufficient to replicate EPO-level effects on dysmenorrhea. However:
- As a dietary supplement taken continuously, spirulina GLA contributes to the daily DGLA pool over weeks and months
- The COX-2 inhibition from phycocyanin adds a second, independent mechanism — directly reducing PGF2α production from arachidonic acid
- Spirulina’s omega-6 GLA is more likely to be beneficial for dysmenorrhea than the generic omega-6 arachidonic acid found in high-meat diets
Phycocyanin: direct COX-2 inhibition for period pain
Phycocyanin’s documented COX-2 inhibition is directly relevant to dysmenorrhea: COX-2 is the enzyme that converts arachidonic acid to the prostaglandins causing cramps. Phycocyanin’s inhibitory potency is lower than ibuprofen, but it is present continuously when spirulina is taken daily — whereas ibuprofen is only present when taken acutely.
There are no dedicated dysmenorrhea-specific spirulina RCTs. The COX-2 mechanism is established for phycocyanin in general inflammation but has not been tested in a uterine-specific or menstrual pain protocol.
Magnesium: another relevant spirulina contribution
Magnesium deficiency is associated with more severe dysmenorrhea — magnesium relaxes smooth muscle, including uterine smooth muscle, and magnesium deficiency increases sensitivity to prostaglandin-induced uterine contractions. A 2001 Cochrane review found magnesium supplementation significantly reduced dysmenorrhea pain scores.
Spirulina provides 30–40 mg magnesium per 5 g — a modest contribution toward the 300–360 mg often used in dysmenorrhea trials. For women with low magnesium intake (common in Western diets), spirulina contributes to improving magnesium status.
Evidence level and honest expectations
Direct clinical evidence for spirulina specifically for dysmenorrhea does not exist. The case is mechanistic:
- GLA → PGE1 anti-inflammatory eicosanoids (plausible mechanism)
- Phycocyanin COX-2 inhibition (established mechanism, unproven in uterine context)
- Magnesium smooth muscle relaxation (established mechanism)
For women with significant dysmenorrhea:
- NSAIDs (ibuprofen 400 mg every 6–8 hours from the day before onset) remain the strongest evidence-based acute intervention
- Evening primrose oil 2–4 g/day (for GLA at therapeutic doses) has more direct dysmenorrhea evidence than spirulina
- Magnesium glycinate 300–400 mg/day has Cochrane-reviewed evidence for dysmenorrhea
- Spirulina is a reasonable daily background supplement addressing these mechanisms at lower intensity over time
Practical guidance
- 5 g/day continuous use — GLA and phycocyanin effects accumulate over weeks; not useful as an acute intervention during the period
- Assess over 2–3 menstrual cycles — prostaglandin balance shifts slowly
- For severe dysmenorrhea: use NSAIDs acutely as needed while using spirulina as ongoing background support
- If endometriosis is the underlying cause, additional specialist assessment is needed — spirulina’s anti-inflammatory mechanisms remain relevant but endometriosis requires dedicated treatment